全文获取类型
收费全文 | 32354篇 |
免费 | 2079篇 |
国内免费 | 259篇 |
专业分类
耳鼻咽喉 | 434篇 |
儿科学 | 591篇 |
妇产科学 | 489篇 |
基础医学 | 3977篇 |
口腔科学 | 1544篇 |
临床医学 | 2659篇 |
内科学 | 8680篇 |
皮肤病学 | 391篇 |
神经病学 | 3300篇 |
特种医学 | 1292篇 |
外科学 | 5225篇 |
综合类 | 93篇 |
一般理论 | 6篇 |
预防医学 | 1312篇 |
眼科学 | 538篇 |
药学 | 1694篇 |
中国医学 | 72篇 |
肿瘤学 | 2395篇 |
出版年
2023年 | 333篇 |
2022年 | 275篇 |
2021年 | 1086篇 |
2020年 | 745篇 |
2019年 | 1022篇 |
2018年 | 1205篇 |
2017年 | 956篇 |
2016年 | 1067篇 |
2015年 | 1130篇 |
2014年 | 1459篇 |
2013年 | 1777篇 |
2012年 | 2776篇 |
2011年 | 2672篇 |
2010年 | 1499篇 |
2009年 | 1363篇 |
2008年 | 2145篇 |
2007年 | 2256篇 |
2006年 | 2029篇 |
2005年 | 1842篇 |
2004年 | 1642篇 |
2003年 | 1493篇 |
2002年 | 1294篇 |
2001年 | 255篇 |
2000年 | 232篇 |
1999年 | 217篇 |
1998年 | 190篇 |
1997年 | 170篇 |
1996年 | 125篇 |
1995年 | 136篇 |
1994年 | 123篇 |
1993年 | 105篇 |
1992年 | 114篇 |
1991年 | 93篇 |
1990年 | 79篇 |
1989年 | 54篇 |
1988年 | 85篇 |
1987年 | 61篇 |
1986年 | 44篇 |
1985年 | 63篇 |
1984年 | 52篇 |
1983年 | 43篇 |
1982年 | 43篇 |
1981年 | 28篇 |
1980年 | 24篇 |
1979年 | 41篇 |
1978年 | 30篇 |
1977年 | 22篇 |
1974年 | 21篇 |
1973年 | 31篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 129 毫秒
71.
72.
73.
74.
Shi-Qiong Xu Simone Buraschi Alaide Morcavallo Marco Genua Tomoaki Shirao Stephen C. Peiper Leonard G. Gomella Ruth Birbe Antonino Belfiore Renato V. Iozzo Andrea Morrione 《Oncotarget》2015,6(13):10825-10839
We recently established a critical role for the growth factor progranulin in bladder cancer insofar as progranulin promotes urothelial cancer cell motility and contributes, as an autocrine growth factor, to the transformed phenotype by modulating invasion and anchorage-independent growth. In addition, progranulin expression is upregulated in invasive bladder cancer tissues compared to normal controls. However, the molecular mechanisms of progranulin action in bladder cancer have not been fully elucidated. In this study, we searched for novel progranulin-interacting proteins using pull-down assays with recombinant progranulin and proteomics. We discovered that drebrin, an F-actin binding protein, bound progranulin in urothelial cancer cells. We characterized drebrin function in urothelial cancer cell lines and showed that drebrin is critical for progranulin-dependent activation of the Akt and MAPK pathways and modulates motility, invasion and anchorage-independent growth. In addition, drebrin regulates tumor formation in vivo and its expression is upregulated in bladder cancer tissues compared to normal tissue controls. Our data are translationally relevant as indicate that drebrin exerts an essential functional role in the regulation of progranulin action and may constitute a novel target for therapeutic intervention in bladder tumors. In addition, drebrin may serve as novel biomarker for bladder cancer. 相似文献
75.
76.
Marco Del Chiaro Caroline Verbeke 《World journal of gastrointestinal pathophysiology》2015,6(2):29-32
Pancreatic cystic neoplasms(PCNs) are a high prevalence disease. It is estimated that about 20% of the general population is affected by PCNs. Some of those lesions can progress till cancer, while others behave in a benign fashion. In particular intraductal papillary mucinousneoplasms of the pancreas can be considered as the pancreatic analogon to colonic polyps. Treatment of these precursor lesions at an early stage can potentially reduce pancreas cancer mortality and introduce a new "era" of preemptive pancreatic surgery. However, only few of those lesions have an aggressive behavior. The accuracy of preoperative diagnosis, i.e., the distinction between the various PCNs is around 60%, and the ability to predict the future outcome is also less accurate. For this reason, a significant number of patients are currently over-treated with an unnecessary, high-risk surgery. Furthermore, the majority of patients with PCN are on life-long follow-up with imaging modality, which has huge cost implications for the Health Care System for limited benefits considering that a significant proportion of PCNs are or behave like benign lesions. The current guidelines for the diagnosis and management of PCNs are more based on expert opinion than on evidence. For all those reasons, the management of cystic tumors of the pancreas remains a controversial area of pancreatology. On one hand, the detection of PCNs and the surgical treatment of pre-cancerous neoplasms can be considered a big opportunity to reduce pancreatic cancer related mortality. On the other hand, PCNs are associated with a considerable risk of under- or over- treatment of patients and incur high costs for the Health Care System. 相似文献
77.
78.
Deferasirox chelation therapy in patients with transfusion‐dependent MDS: a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 下载免费PDF全文
Luca Maurillo Massimo Breccia Francesco Buccisano Maria Teresa Voso Pasquale Niscola Giulio Trapè Caterina Tatarelli Ada D'Addosio Roberto Latagliata Susanna Fenu Anna Lina Piccioni Alberto Fragasso Maria A. Aloe Spiriti Marco Refrigeri Marianna Criscuolo Pellegrino Musto Adriano Venditti 《European journal of haematology》2015,95(1):52-56
Deferasirox (DFX) is an orally administered iron chelator approved for use in patients with transfusion‐dependent iron overload due to myelodysplastic syndromes (MDS). The safety and efficacy of DFX has been explored in clinical trial settings, but there is little data on unselected patients with MDS. The aim of this study was to retrospectively evaluate the safety, compliance, efficacy and effect on haematopoiesis of DFX in a large ‘real‐world’ MDS population. One hundred and eighteen patients with transfusion‐dependent MDS were treated with DFX across 11 centres in Italy. Serum ferritin levels, haematological response, dosing, adverse events and transfusion dependence were recorded at baseline, 3, 6, 12 and 24 months following initiation of treatment. DFX reduced mean serum ferritin levels from 1790 to 1140 ng/mL (P < 0.001), with 7.1% of patients achieving transfusion independence. Significant haematological improvement was seen in erythroid (17.6%), platelet (5.9%) and neutrophil counts (7.1%). Adverse events were reported in 47.5% of patients, including gastrointestinal and renal toxicity. Regression analysis showed that higher starting doses of DFX are associated with transfusion independence at 24 months. DFX is a safe, effective treatment for transfusion‐dependent MDS that can lead to transfusion independence and haematological improvement in a subset of patients. 相似文献
79.
Wojciech Szychta M.D. Ph.D. Gheorghe Cerin M.D. Ph.D. F.E.S.C. Bogdan Adrian Popa M.D. Armienti Felice M.D. Guido Lanzillo M.D. Ph.D. Marco Diena M.D. Grzegorz Opolski M.D. Ph.D. F.E.S.C. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(6):1040-1043
Sinus venosus atrial septal defect (SV‐ASD) usually coexists with partial anomalous pulmonary vein connection (PAPVC). It is a difficult diagnosis in transthoracic echocardiography (TTE) due to eccentric position of defects. We present a rare case of atypical anatomical variation in PAPVC, which was never described before. Two right pulmonary veins drained into superior vena cava, which overrode SV‐ASD and interatrial septum, a third pulmonary vein into the right atrium. Complete diagnosis could not be set after TTE, nor transesophageal echocardiography, whereas angio‐CT was finally conclusive. This diagnostic approach allowed the surgical planning. 相似文献
80.